Telo Genomics Announces that Positive Results of Smoldering Multiple Myeloma Study Selected for Online Publication Within ASH 2020 Proceedings

NEXT STORY
Microbiome Therapeutics: Global Markets
PREV STORY
AnaptysBio Reports Positive Topline Data from GALLOP Phase 2 Clinical Trial of Imsidolimab in Moderate-to-Severe Generalized Pustular Psoriasis (GPP)
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

TESARO Receives Positive CHMP Opinion for ZEJULA®

ZUG, Switzerland, Sept. 15, 2017 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical ...

author_avatar
NASDAQ Market News

Histogenics Corporation to Present at the 2017 Cell & Gene Meeting on the Mesa

WALTHAM, Mass., Sept. 26, 2017 (GLOBE NEWSWIRE) -- Histogenics Corporation (Histogenics) (Nasdaq:HSGX), a leading ...

author_avatar
NASDAQ Market News

GILEAD AND GALAPAGOS ANNOUNCE FILGOTINIB MEETS PRIMARY AND ALL KEY SECONDARY ENDPOINTS IN FIRST PHASE 3 STUDY IN RHEUMATOID ARTHRITIS

-- Filgotinib 100 mg and 200 mg Doses Achieved Significantly Higher ACR20/50/70 Responses than ...

author_avatar
NASDAQ Market News